Lenalidomide plus dexamethasone for proliferative glomerulonephritis with monoclonal immunoglobulin deposits
10.3760/cma.j.cn441217-20191112-00083
- VernacularTitle:来那度胺联合地塞米松治疗伴单克隆免疫球蛋白沉积的增生性肾小球肾炎
- Author:
Houan ZHOU
1
;
Jingjing CHEN
;
Manna LI
;
Xia WANG
;
Caihong ZENG
;
Xianghua HUANG
;
Zhaohong CHEN
;
Zhen CHENG
Author Information
1. 南京大学医学院附属金陵医院（东部战区总医院）肾脏病科，南京 210016；东部战区总医院 国家肾脏疾病临床医学研究中心，南京 210016
- From:
Chinese Journal of Nephrology
2020;36(6):441-446
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of lenalidomide plus dexamethasone (LD) in patients with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).Methods:The clinicopathological data of PGNMID patients who were treated with LD protocol from January 2010 to October 2019 were retrospectively analyzed.Results:All of 6 patients received LD treatment for≥3 months after renal biopsy in Jinling Hospital. During the follow-up period of 6 to 19 months, 3 patients achieved renal remission, and the renal remission rate was 50%(3/6). Light microscopy showed membranoproliferative glomerulonephritis and immunofluorescence showed single kappa type IgG3 was deposited in the mesangial region and the vascular loop. Before taking LD scheme, the median urinary protein were 7.76(1.27, 14.57) g/24 h, the median serum creatinine was 118.5(70.7, 289.1) μmol/L, and the median albumin was 34.5(22.4, 37.5) g/L. The concentration of serum free kappa and lambda light chain was increased in 5 patients, but the serum free light chain ratio was normal. Hypocomplementemia was detected in two cases. Six patients underwent bone marrow flow cytometry, and 2 patients had elevated monoclonal plasma cells, accounting for 0.7% and 0.5%, respectively. Immunofixation electrophoresis suggested that 1 patient had positive serum M protein for kappa type IgG3. At the last follow-up, median urine protein was 3.33(0.33, 11.23) g/24 h, median serum creatinine was 108.7(80.4, 160.9) μmol/L, and median albumin was 35.9(24.5, 45.6) g/L. The concentration of serum free light chain in 4 patients from 5 patients with elevated serum free light chain was lower than that before taking the drug. Decreased level of serum complement in two cases returned to normal after treatment. The M spike did not turn negative during the follow-up in one patient. Adverse events included anemia, neutropenia, limb numbness and upper respiratory tract infection.Conclusion:This study reports for the first time that LD protocol may be effective in treating PGNMID, but more attention should be paid to the hematological adverse events of lenalidomide.
